| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Large Scale Biology Corporation |
| 3333 Vaca Valley Parway, Suite 1000, Vacaville, CA 95688 * (707) 446-5501 |
| Business Description | The company applies its proprietary proteomics and functional genomics technologies to develop products and establish commercial collaborations with pharmaceutical, biotechnology, chemical and other life sciences companies. |
| Offering Information Company has | |||
| Trading As | LSBC (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 4/6/00 |
| Domestic Shares Offered | 5,000,000 | Offer Date | 8/9/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 5,000,000 | Offer Price | $17.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.190 |
| Gross Proceeds | $85,000,000 | Selling | $0.710 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 15,480,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| J.P. Morgan & Co. | Lead Manager | (212) 648-0517 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| William Blair & Company | Co-manager | (312) 364-8990 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 2.108 | 3.394 | 16.090 | - | - |
| Income from Oper. | - | - | -8.862 | -9.636 | -29.177 | - | - |
| Net Income | - | - | -6.569 | -9.421 | -27.727 | - | - |
| E.P.S | - | - | -1.060 | -1.700 | -5.380 | - | - |
| Revenue Growth (%) | - | - | 61.01 | 374.072 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | 6.30 | - | - | ||||
| Cash Flow - Inv. | -8.45 | - | - | ||||
| Cash Flow - Fin. | 5.64 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 31.60 | Current Assets | 15.22 | Current Ratio | 0.91 |
| Total Liab. | 27.09 | Current Liab. | 16.73 | Debt Ratio | 85.70% |
| Total Equity | 4.52 | Working Cap. | -1.51 | Debt to Equity Ratio | 5.99 |
| Cash | 6.98 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, product development initiatives, capital expenditures and working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Brobeck, Phleger & Harrison |
| Bank's Law Firm | Cahill Gordon & Reindel |
| Registrar/Transfer Agent | EquiServe |
| Auditor | Deloitte & Touche |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Technology Directors II, LLC | 21.30 | |
| The Dow Chemical Company | 10.40 | |
| Technology Directors II BST, LLC | 6.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||